Patent Grant
9603923
The invention relates to a universal polypeptidic carrier for targeting molecules to a Gb3 receptor for the B-subunit of Shiga-Toxin expressing cells and its use for intracellular transport and processing of said molecules.
Shiga Toxin is a bacterial toxin of the AB5 subunit family that is secreted by Shigella dysenteriae. The A-subunit is the toxic moiety and inhibits the protein synthesis in higher eucaryotic target cells after transfering into the cytoplasm of said cells. The B-subunit is an homopentamer protein (5B—fragments) and is responsible for toxin binding to and internalization into target cells by interacting with the glycolipid Gb3 found on the plasma membranes of these cells. The B-fragment is non toxic, but conserves the intracellular transport characteristics of the holotoxin which, in many Gb3 expressing cells, is transported in a retrograde fashion from the plasma membranes to cytosol, via endosomes.
The glycolipid Gb3 receptor has also been reported to be expressed preferentially in some ectodermic derived tumors (plasma) and some Burkitt's lymphoma. It is also known as CD 77. In the present text, the term Gb3 should be considered as an equivalent to CD77.
The authors have already shown that a CD8 human tumor Antigen fused to the B subunit of Shiga toxin could efficiently be presented in an HLA class I-restricted manner to specific CTL (1). This result was independently confirmed by another study that demonstrated that Shiga holotoxin, carrying a defined peptide epitope from influenza virus, could deliver the antigen into the MHC class I intracellular pathway (3).
The authors have also shown that fusion proteins between the Gb3 receptor-binding non toxic B-fragment of bacterial Shiga toxin derived from Shigella dysenteriae and an antigen, or an epitope from a model tumor antigen, can elicit specific cytotoxic T lymphocytes response (CTL), whereas each moiety of said fusion protein does not lead individually to CTL induction (1, 2, and WO 99/03881).
The difficulty of this technology is that, for each application, i.e., for each antigen or fragment thereof, there is a need for a specific construction of a fusion protein, that necessitates a specific construction of a recombinant vector bearing the sequences encoding this fusion protein to be expressed in a host cell.
The aim of the present invention is to overcome the above-mentioned drawbacks and to provide a universal hook, or a universal carrier for targeting a molecule to a Gb3 receptor expressing cell to enable this molecule to be internalized, processed and/or expressed in said cell expressing Gb3 receptor.
In the present invention, a Shiga toxin B-subunit (STxB) derivative, or mutant, termed STxB-Cys has been designed. In this protein, a Cysteine is added at the C-terminus of mature STxB. The protein, when purified from bacteria, carries the internal disulfide bond, as wild type STxB, while the sulfhydryl group at the C-terminal Cys is free. Due to their nucleophilicity, free sulfhydryl groups are excellent acceptors for directed coupling approaches (4).
Thus, the present invention relates to a universal polypeptidic carrier for targeting directly or indirectly a molecule of interest to Gb3 receptor expressing cells having the following formula: STxB-Z(n)-Cys, wherein:
The STxB moiety of the universal carrier has the sequence described in (8) or a functional equivalent thereof. A functional equivalent means a polypeptidic sequence having the capacity to bind specifically to the Gb3 receptor and/or to trigger an internalization of an antigen and its presentation in an MHC class-I restricted pathway, or both MHC class I and class II on the same antigen presenting cell.
In the light of the heterogeneity of expression of tumor antigens, the allele-specific loss of MHC class I expression at the surface of tumor cells, and the necessity to have concomitant presentation of antigens by both MHC class I and class II on the same antigen presenting cell, it is advantageous to couple full size antigen proteins to the B-subunit for targeting to dendritic cells.
In a preferred embodiment, n is 0 and the universal carrier has the following sequence (SEQ ID No 1):
As a matter of fact, if the Z linker is too long, i.e., when n is equal or greater than 2, some internal disulfide bridges might occur, and prevent either the binding of STxB to the Gb3 receptor and especially prevent the binding to the molecule of interest.
According to the invention, the molecule of interest is selected in the group constituted of proteins, peptides, oligopeptides, glycoproteins, glycopeptides, nucleic acids, polynucleotides, or a combination thereof.
In another aspect of the invention, the molecule of interest is an antigen to be targeted to antigen presentating cells. Such cells are selected in a group comprising T lymphocytes, dendritic cells, macrophages Langerhans cells and the like.
In another aspect of the invention, the molecule of interest are drugs such as haptenes, psoralenes, or any compounds provided that they have a chemical group linkable with the —SH group of the Cysteine moiety of STxB-Cys.
The drug might be linked either directly or after activation with coumpounds such as bromoacetate, or any other method known by a skilled person, provided that the result of the reaction is a chemical entity having the following formula: STxB-Cys-M, M being all the above mentioned molecules of interest.
The coupling approaches for covalent binding of a peptidic or a polypeptidic moiety to STxB-Z(n)-Cys can be any method or processes described or carried out by a skilled person.
A first method that can be embodied is the use of SPDP hetero-bi-functional cross-linker described par Carlsson et al (5). However, SPDP is capable of being cleavable by serum thiolases that is a cause of decreasing the yield of the reaction.
A second method for covalent coupling of STxB-Z(n)-Cys peptides with another peptide of interest is to produce bromoacetyl or maleimide functions on the latter as described by P. Schelte et al (4). Briefly, the peptide of interest is chemically activated with bromoacetate anhydride or by a maleimide group respectively. In appropriate reaction conditions (pH, temperature, incubation times), these groups are eliminated by cis-elimination, yielding respectively to —S—S, —S—CH2—, to —S—CO— or to —S—NH— covalents linkages.
As an example, the polypeptide or the peptide to be coupled to the —SH moiety the C-terminal Cysteine of the universal carrier, has its N-terminus activated with bromoacetic anhydride following the reaction scheme:
Br—CH2—CO—O—CO—CH2—Br+NH2-peptideBr—CH2—CO—NH-peptide+Br—CH2—COOH
The Bromoacetyl function has high chemoselectivity for peptide thiol groups and the activated peptide can be reacted with STxB-Cys as follows:
STxB-Cys-SH+Br—CH2—CO—NH-peptideSTxB-Cys-S—CH2—CO—NH-peptide+HBr
The resulting thioether-linkage is stable to hydrolysis.
Another method for coupling a molecule to the universal carrier of the invention is to use MBS (m-Maleimidobenzoyl-N-hydroxysuccinimide ester) as shown in
Thus, another aspect of the invention is the product resulting from a covalent binding of STxB-Z(n)-Cys with a molecule of interest by a —S—S—, —S—CO—, or S—CH2- or —S—NH— linkage.
In one embodiment, the molecule of interest to be targeted to an antigen presentating cells is constituted by or comprises a polypeptidic structure, such an antigens or epitopes thereof, glycopeptides or glycoproteins, lipopeptides or lipoproteins.
In a preferred embodiment, the product resulting from the coupling of STxB-Z(n)-Cys with an antigen or a fragment thereof, where (n) is 0, 1, or 2, and preferably 0, is able to be presented in an MHC class I and MHC class II restricted pathway.
In another embodiment, the molecule of interest is a polypeptide capable of binding with polynucleotide structures such as DNA or RNA molecules. Such molecules might be vectors or plasmids comprising a sequence of interest to be expressed in a target cell. In the present invention, a target cell is a eucaryotic cell bearing on its membrane the Gb3 receptor.
Thus, the universal carrier of the present invention is also a carrier for introducing a nucleotide sequence in a target cell either for gene therapy or for obtaining recombinant cells expressing heterologous proteins.
In another embodiment, the universal carrier according to the present invention can be operably linked directly through a covalent binding or indirectly through a linker to a cytotoxic drug to be targeted to tumor cells expressing Gb3 receptor.
The term “indirect binding” means that the universal carrier is covalently linked through the sulfhydryl moiety of the C-terminal Cysteine to a linker, said linker being operably linked to a drug or a pro-drug to be internalized into Gb3 receptor bearing cells.
This linkage might be a covalent binding or a non-covalent binding, provided that the affinity between the linker and the drug (or the pro-drug) is higher than 10−9 mole/l.
Another aspect of the invention is an isolated polynucleotide selected from the group of.
In a preferred embodiment, the polynucleotide has the following SEQ ID No 2:
The present invention relates also to a recombinant vector or to a plasmid comprising a polynucleotide sequence as described above, and capable of expressing the universal carrier STxB-Z(n)-Cys, where (n) is 0, 1 or 2, STxB and Z have the same significance as above, in an appropriate host cell.
As an example, a convenient vector is the plasmid pSu108 described in (7).
Another object of the present invention is to provide a method for obtaining a plasmid expressing STxB-Z(n)-Cys comprising:
a) providing a plasmid comprising a STxB sequence;
b) applying two PCR amplification steps using two couples of primers, A′ and BB′,
c) isolating the amplified fragments;
d) hybridizing the amplified fragments;
e) applying a PCR amplification on the hybridized fragments;
f) insertion of the amplified fragment into a plasmid.
In a preferred embodiment, the plasmid pSU108 (7) containing STxB fragment was modified to introduce the Cysteine codon TGT at the 3′ end of the B-fragment cDNA. The primers for step b) are respectively for AA′ and BB′:
The PCR of step e) yields a fragment that is cloned into the SphI and SalI restriction sites of pSU108. Sequences derived by PCR are verified by dideoxy-sequencing.
The skilled person can easily design the choice of primers, plasmids for producing a vector bearing the polynucleotide sequence expressing STxB-Z(n)-Cys in an appropriate host cell, provided that this succession of steps allows the interpretation of the Cys codon into the amplified fragment.
The invention also provides a recombinant cell line obtained by transformation with the recombinant vector containing the polypeptide sequence encoding the universal carrier as described above. In a preferred embodiment, said recombinant cell line is a procaryotic cell, preferentially E. coli.
In a still preferred embodiment, the plasmid is pSU108 having SEQ ID No. 2 integrated between the SphI and SalI restriction sites, and the corresponding cell line has been deposited at CNCM on Dec. 19, 2000 with the registration number I-2604.
The present invention also provides a process for producing a universal carrier as described above comprising:
Preferentially, the cell line is E. coli and in c) the purification is made by anion exchange column chromatography followed by a gel filtration column chromatography.
Such a process is particularly advantageous for large scale production of the universal carrier, as far as it can then be operably linked by covalent coupling with a molecule of interest, and used within a large scope of application.
The present invention also provides a method for delivering a sequence of interest into the MHC class I pathway using a product obtained by covalent binding of the Cys moiety of the universal carrier with said sequence of interest; this method is advantageous to elicit a CTL response to a given antigen or epitope thereof as far as the product is specific to the cell involved in the MHC class I pathway.
As a matter of fact, the inventors have shown that an immunodominant peptide, derived from the ovalbumin protein, and coupled chemically to STxB-Cys, could be presented by antigen presenting cells to specific hybridoma cells, demonstrating that STxB could deliver exogenous immunogenic peptide in the MHC class I pathway. To exclude a bias due to the presence of free peptides contaminating the material, experiments using fixed dendritic cells clearly demonstrated that the internalization of the fusion protein was required for this process. The inventors also have shown that the Shiga toxin receptor, Gb3, was also involved in the ability of STxB-Cys to target exogenous peptide in the endogenous MHC class I pathway.
The invention also pertains to a method for delivering an expression vector containing a sequence of interest into a Gb3 receptor expressing cells characterized in that said expression vector is bound to a lysine rich peptide covalently linked to the Cys moiety of the universal carrier.
As an example, the lysine rich peptide is a 16-mer poly-lysine which is able to bind any polynucleotidic sequence, either of DNA or RNA nature. Such a peptide carrying a 16-mer of lysines will be activated at its N-terminus by bromoacetate anhydride and coupled to STxB-Cys. Expression plasmids will be bound to this coupling product, and vectorization of DNA into target cells is assayed using convenient reporter systems, such as the green fluorescent protein or luciferase.
The capacity to target expression plasmids with the help of STxB to the nucleus of antigen presenting cells is expected to further improve the power of this vector, since i) DNA can even more easily be adopted to new experimental or clinical needs, and ii) due to its potentiation effect, expression of antigenic peptides or proteins from DNA would further increase the sensitivity of STxB-dependent antigen presentation.
The invention also provides a method for delivering a drug or a pro-drug into a cell, particularly into a cancer cell bearing Gb3 (or CD77) receptor.
The glycolipid Gb3 receptor has been reported to be preferentially expressed in some neuroectodermic derived tumors (glioma) and some Burkitt's lymphoma. Since one limitation of the use of chemotherapy in cancer is secondary side effects of the drugs because of their toxicity on normal cells, the drugs are preferentially vectorized in tumor cells by using STxB-Cys. The drugs are activated to become reactive with the sulfhydryl group of STxB-Cys. To achieve this, a maleimide group can be introduced on a drug, for example psoralenes compounds.
The present invention also pertains to:
Without limiting the scope of the universal carrier of the invention and its widespread use in different applications, the hereinafter examples and figures illustrate the advantages of the present invention.
a) Construction of a Plasmid Expressing STxB-Cys:
In a preferred embodiment, the plasmid pSU108 (7) was modified to introduce the Cysteine codon tgt at the 3′ end of the B-fragment cDNA. PCR primer A: SEQ ID no 3 (5′-AGCGAAGTTATTTTTCGTTGTTGACTCAGAATAGCTC-3′) and primer A′: SEQ ID no 4 (5′-GAGCTATTCTGAGTCAACACGAAAAATAACTTC-3′) were used with plasmid specific primers ShigaAtpE: SEQ ID no 5 (5′-CACTACTACGTTTTAAC-3′) and Shiga-fd: SEQ ID no 6 (5′-CGGCGCAACTATCGG-3′) to produce DNA fragments which, in a second PCR with primers Shiga AtpE and Shiga-fd yielded a fragment that was cloned into the SphI and SalI restriction sites of pSU108. Sequences derived by PCR were verified by dideoxy-sequencing.
b) Protein Purification:
b) 1. Preparation of the Periplasmic Extract was Performed as Follows:
b) 2. Purification on Columns:
The periplasmic extract was loaded on a QFF anion exchanger column (pharmacia) and eluted at 230 mM NacI. STxB-Cys containing fractions are pooled, diluted 4-fold and loaded on a Mono Q anion exchanger column (pharmacia), followed by elution at 230 mM NacI. After concentration with microconcentration devices from PallFiltron, the pooled fractions were passed through a Sephadex 75 gel filtration column. Purity was above 95% (
b) 3. Product Characterization:
The B-fragments of STxB-Cys, purified from Sephadex 75 gel filtration columns, are essentially monomeric (
a) Carriers:
Three different carriers have been compared.
1) STxB-Cys: B-fragment to which a Cys has been added right to its C-terminus. This protein elutes as a monomer from the purification columns.
2) STxB-Z2-Cys: carrier with a short spacer (2 amino acids resulting from a cloning cassette) between the C-terminus of the wild type B-fragment and the Cys. The majority of the protein eluted as dimers from the purification columns. These can be separated under reducing conditions, indicating the formation of disulfide bonds between monomers in the pentameric B-subunit complex.
3) STxB-Glyc-Cys-KDEL: carrier in which the Cys is located between a Glycosylation cassette being 9 amino acid long and a C-terminal KDEL peptide. The majority of the protein eluted as dimers from the purification columns. These can be separated under reducing conditions, indicating the formation of disulfide bonds between monomers in the pentameric B-subunit complex.
b) Test Peptides:
1) Pep1: a synthetic peptide of 16 amino acids carrying the SL8 antigenic peptide derived from chicken ovalbumin.
2) Pep2: a synthetic peptide of 24 amino acids as above with, in addition, a His-gag at its C-terminus.
3) SL8: the antigenic peptide from ovalbumin that can directly exchange with peptides on MHC class I complexes at the plasma membrane of antigen presenting cells.
c) Coupling Conditions:
Under reducing conditions (Type1): Fusion proteins were treated with DTT overnight, then activated peptide (carrying a bromo acetate group at its N-terminus) was added in excess. Conditions used for the first coupling experiments using fusion proteins will mostly dimerize monomers (proteins STxB-Z2-Cys and STxB-Glyc-Cys-KDEL).
Under non-reducing conditions (Type2): Fusion proteins are directly reacted with the activated peptides.
d) Biochemical and Morphological Controls:
Pep2 carries a His-tag. This has allowed us, using an anti-His antibody, to show the presence of Pep2 on B-subunit by Western blotting, and the B-subunit dependent transport of Pep2 in HeLa cells.
Note that antigen presentation only works on non-fixed cells, indicating that the observed presentation does not result from contaminating free Pep2.
In
In
In
It appears from all these experiments that the coupling under non-reducing to STxB-Cys is surprisingly efficient (in terms of sensitivity; note that, as shown in
Hence, the optimal conditions for coupling of activated peptides to STxB-Cys were the following:
The following experimental series will help to fully describe the capacity of STxB to function in antigen presentation system.
a) Class I- and Class II-restricted Antigen Presentation:
A peptide carrying class I- and II-restricted antigenic peptides from chicken ovalbumin (Br—CH2-CO—NH-LEQLESIINFEKLTEWSLKISQAVHAAHAEINEAGR (SEQ ID NO:6), sequences 257-264 and 323-339 were coupled to STxB-Cys, and the class I- and class II-restricted presentation of these peptides were assayed using the corresponding T-cell hybridomas.
b) Coupling of Whole Size Proteins.
Our preliminary evidence suggests that chicken ovalbumin can be coupled to STxB-Cys. These experiments have been done with the SPDP heterobifunctional cross-linker. (Carlsson et al., 1978).
A first series of antigen presentation experiments indicated that the ovalbumin protein can be introduced into the endogenous MHC class I-restricted antigen presentation pathway of mouse dendritic cells. SPDP has the inconvenience of being cleavable by serum thiolases. This cross-linker was successfully substituted by MBS which is non-cleavable. Other antigenic proteins (Mart 1 and polypeptides derived from HPV16-E7 and Muc1) are tested to show that the procedure is of universal use.
c) Coupling of Complex Protein Mixtures.
A lysate from the cervix carcinoma-derived cell line Caski is used. This cervix carcinoma cell line, which expresses the HLA-A2 allele at its membrane, also expresses Human papillomavirus derived peptides. E7 is a early transcribed ORF from HPV which is necessary for transformation of primary keratinocytes. Since anti-E7 HLA A2-restricted CTL are elicited in vitro. The efficacy of the coupling of this protein mixture by a presentation assay specific for HLA-A2 E7 derived peptides was tested. As control, a lysate from a HLA-A2-positive cell line which does not express E7 (croft cells or Daudi) was coupled to STxB-lys.
The experiment of
The reaction scheme is shown in
In a first reaction, the N-hydroxysuccinimide ester moiety of MBS reacts with primary amines on an antigenic target protein, such as the model protein ovalbumin (Ova). The reaction product is purified and then incubated in a second reaction with STxB-Cys leading to coupling via the maleimidobenzoyl moiety.
0.5 μM of STxB-Cys-Ova was incubated with HeLa cells on ice. The cells were washed and shifted to 37° C. for 45 min, fixed, and stained for the indicated antibodies. As shown in
In a first experiment (
In a second experiment, we have pulsed the same D1 dendritic H2b restricted cell line with either Ova alone or with STxB-Cys-Ova. No presentation of the Ova-derived immunodominant SL8 peptide (Ova257-264) was observed when the D1 cells were sensitized with up to 100 nM of free Ova, while 1-10 nM of STxB-Cys-Ova allowed the presentation of the SL8 peptide, as revealed by the specific B3Z hybridoma that recognize the SL8 peptide in the context of Kb molecules. As a control, it was shown that no activation of an irrelevant hybridoma was observed under the same experimental conditions.
Altogether, these results clearly demonstrate that STxB-Cys targets full size proteins with high efficiency into both, the MHC class I and class II pathways.
(1) Ren-Shiang Lee, Eric Tartour, Pierre van der Bruggen, Valérie Vantomme, Isabelle Joyeux, Bruno Goud, Wolf Herman Fridman and Ludger Johannes, “Major histocompatibility complex class I Presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin”. Eur. J. Immunol. (1998) 28: 2726-2737.
(2) Nacilla Haicheur, Emmanuelle Bismuth, Sophie Bosset, Olivier Adotevi, Guy Warnier, Valérie Lacabanne, Armelle Regnault, Catherine Desaymard, Sebastian Amigorena, Paola Ricciardi-Castagnoli, Bruno Goud, Wolf H. Fridman, Ludger Johannes and Eric Tartour, “The B Subunit of Shiga Toxin Fused to a Tumor Antigen Elicits CTL and Targets Dendritic Cells to Allow MHC Class I-Restricted Presentation of Peptides Derived from Exogenous Antigens”. The Journal of Immunology (2000) 10: 3301-3308.
(3) Noakes, K. L., H. T. Teisseranc, J. M. Lord, P. R. Dunbar, V. Cerundolo and L. M. Roberts “Exploiting retrograde transport of Shiga-like toxin 1 for the delivery of exogenous antigens into the MHC class I presentation pathway”. Febs. Lett. (1999) 453:95.
(4) Philippe Schelté, Christophe Boeckler, Benoît Frisch and Francis Schuber “Differential Reactivity of Maleimide and Bromoacetyl functions with Thiols: Application to the Preparation of Liposomal Diepitope Constructs”. Eur. J. Immunol. (1999) 29:2297-2308.
(5) Carisson, J., H. Drevin, and R. Axen. 1978. Protein thiolation and reversible protein-protein conjugation. N-Succinimidyl 3-(2-pyridyldithio)propionate, a new heterobifunctional reagent. Biochem. J. 173:723-737.
(6) Su, G. F., H. N. Brahmbhatt, J. Wehland, M. Rohde and K. N. Timmis “Construction of stable LamB-Shiga toxin B subunit hybrids: analysis of expression in Salmonella typhimurium aroA strains and stimulation of B subunit-specific mucosal and serum antibody responses”. (1992) Infect. Immun. 60:3345-3359.
(7) Johannes, L., Tenza, D., Antony, C. and Goud, B., “Retrograde transport of KDEL-bearing B-fragment of Shiga toxin”. (1997) J. Biol. Chem. 272: 19554-19561.
(8) N. A. Stockbine, M. P. Jackson, L. M. Sung, R. K. Holmes, A. D. O'Brien, J Bacteriol 170, 1116-22 (1988).
| Number | Date | Country | Kind |
|---|---|---|---|
| 01400255 | Feb 2001 | EP | regional |
This is a divisional of co-pending U.S. patent application Ser. No. 12/569,007 filed Sep. 29, 2009, which is a divisional of U.S. patent application Ser. No. 10/628,415 filed Jul. 29, 2003, issued as U.S. Pat. No. 7,632,514 on Dec. 15, 2009, which is a continuation application of PCT Application No. PCT/EP02/01627 filed on Feb. 1, 2002, and which claims priority under 35 U.S.C. §119(a) to Patent Application No. EP01400255.4 filed in Europe on Feb. 1, 2001, the entire contents of each of the above-identified applications are hereby incorporated by reference.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4810643 | Souza | Mar 1989 | A |
| 5994311 | Eichner et al. | Nov 1999 | A |
| 6613882 | Goud et al. | Sep 2003 | B1 |
| 6652857 | Williams et al. | Nov 2003 | B2 |
| 6777202 | Lubitz et al. | Aug 2004 | B2 |
| 6855321 | Rappuoli et al. | Feb 2005 | B1 |
| 7488809 | Goud et al. | Feb 2009 | B2 |
| 7632514 | Johannes et al. | Dec 2009 | B2 |
| 7718601 | Johannes et al. | May 2010 | B2 |
| 7981400 | Johannes et al. | Jul 2011 | B2 |
| 8293245 | Smith et al. | Oct 2012 | B2 |
| 8313731 | Johannes et al. | Nov 2012 | B2 |
| 8524652 | Goud et al. | Sep 2013 | B2 |
| 8685408 | Tartour | Apr 2014 | B2 |
| 8846058 | Smith | Sep 2014 | B2 |
| 8852612 | Johannes | Oct 2014 | B2 |
| 8969529 | O'Brien | Mar 2015 | B2 |
| 9034868 | Gillet | May 2015 | B2 |
| 9226957 | Bottje | Jan 2016 | B2 |
| 20040047883 | Goud et al. | Mar 2004 | A1 |
| 20040110935 | Johannes et al. | Jun 2004 | A1 |
| 20060008475 | Johannes et al. | Jan 2006 | A1 |
| 20090035330 | Dewerchin | Feb 2009 | A1 |
| 20090092578 | Su et al. | Apr 2009 | A1 |
| 20100196417 | Tartour | Aug 2010 | A1 |
| 20100196418 | Johannes | Aug 2010 | A1 |
| 20100266672 | Garcon et al. | Oct 2010 | A1 |
| 20100322913 | Goud et al. | Dec 2010 | A1 |
| 20100329992 | Johannes et al. | Dec 2010 | A1 |
| 20110318357 | O'Brien | Dec 2011 | A1 |
| 20150045536 | Johannes | Feb 2015 | A1 |
| Number | Date | Country |
|---|---|---|
| 1229045 | Aug 2002 | EP |
| 1386927 | Feb 2004 | EP |
| 1938836 | Jul 2008 | EP |
| 2766193 | Jan 1999 | FR |
| WO 9511998 | May 1995 | WO |
| WO 9903881 | Jan 1999 | WO |
| WO 02060937 | Aug 2002 | WO |
| WO 2004016148 | Feb 2004 | WO |
| WO 2008080926 | Jul 2008 | WO |
| Entry |
|---|
| Garcia-Castillo et al, Journal of Cell Science (2015) 128, 2373-2387 doi:10.1242/jcs.169383. |
| Andrade et al, Human Vaccines & Immunotherapeutics 10:10, 2864-2874; Oct. 2014. |
| Bartkowski et al., “Aggregation of Recombinant Bovine Granulocyte Colony Stimulating Factor in Solution”, Journal of Protein Chemistry, vol. 21, No. 3, Mar. 2002, pp. 137-143. |
| Bast et al., “The identification of three biologically relevant globotriaosyl ceramide receptor binding sites on the Verotoxin 1 B subunit”, Molecular Microbiology, vol. 32, No. 5, 1999, pp. 953-960. |
| Calderwood et al., “Nucleotide sequence of the Shiga-like toxin genes of Escherichia coli”, Proc. Natl. Acad. Sci. USA, Biochemistry, vol. 84, Jul. 1987, pp. 4364-4368. |
| Carlsson et al., “Protein Thiolation and Reversible Protein-Protein Conjugation”, Biochem. J., vol. 173, 1978, pp. 723-737. |
| Dubos et al., “Preparation and Properties of Shiga Toxin and Toxoid”, J. Exp. Med., vol. 56, 1946, pp. 143-156. |
| Gaidamakova et al., “Molecular vehicle for target-mediated delivery of therapeutics and diagnostics”, Journal of Controlled Release, vol. 74, Issues 1-3, Jul. 6, 2001, pp. 341-347. |
| Gariépy, “The use of Shiga-like toxin 1 in cancer therapy”, Critical Reviews in Oncology/Hematology, vol. 39, 2001, pp. 99-106. |
| Hagnerelle et al., “Two-dimensional structures of the Shiga toxin B-subunit and of a chimera bound to the glycolipid receptor Gb3”, Journal of Structural Biology, vol. 139, 2002, pp. 113-121. |
| Haicheur et al., “The B Subunit of Shiga Toxin Fused to a Tumor Antigen Elicits CTL and Targets Dendritic Cells to Allow MHC Class I-Restricted Presentation of Peptides Derived from Exogenous Antigens”, The Journal of Immunology, vol. 165, 2000, pp. 3301-3308. |
| Herold et al., “Shiga toxin-encoding bacteriophages-genomes in motion”, International Journal of Medical Microbiology, vol. 294, 2004, pp. 115-121. |
| International Search Report, dated Jul. 23, 2002, for International Application No. PCT/EP02/01627. |
| Ishikawa et al., “The Substitution of Cysteine 17 of Recombinant Human G-CSF with Alanine Greatly Enhanced its Stability”, Cell Structure and Function, vol. 17, 1992, pp. 61-65. |
| Johannes et al., “Retrograde Transport of KDEL-bearing B-fragment of Shiga Toxin”, The Journal of Biological Chemistry, vol. 272, No. 31, Aug. 1, 1997, pp. 19554-19561. |
| Jones et al., “Variable linking region immunogenicity using malarial peptide carrier protein conjugates of defined composition”, Immunology Letters, vol. 26, 1990, pp. 285-290. |
| Kim et al., “Tetanus toxin C-fragment as a universal carrier protein for conjugate vaccines”, Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, vol. 43, 2003, p. 294, abstract only provided. |
| Lee et al., “Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin”, Eur. J. Immunol., vol. 28, 1998, pp. 2726-2737. |
| Ling et al., “A mutant Shiga-like toxin IIe bound to its receptor Gb3: structure of a group II Shiga-like toxin with altered binding specificity”, Structure, vol. 8, No. 3, Feb. 22, 2000, pp. 253-264. |
| Ling et al., “Structure of the Shiga-like Toxin I B-Pentamer Complexed with an Analogue of Its Receptor Gb3”, Biochemistry, vol. 37, 1998 (Published on the Web Feb. 3, 1998), pp. 1777-1788. |
| Lu et al., “Isomers of Epidermal Growth Factor with Ser → Cys Mutation at the N-Terminal Sequence: Isomerization, Stability, Unfolding, Refolding, and Structure”, Biochemistry, vol. 44, 2005 (Published on the Web Oct. 22, 2005), pp. 15032-15041. |
| Makino et al., “Genetically modified Shiga toxin 2e (Stx2e) producing Escherichia coli is a vaccine candidate for porcine edema disease”, Microbial Pathogenesis, vol. 31, 2001, pp. 1-8. |
| Mallard et al., “Direct Pathway from Early/Recycling Endosomes to the Golgi Apparatus Revealed through the Study of Shiga Toxin B-fragment Transport”, The Journal of Cell Biology, vol. 143, No. 4, Nov. 16, 1998, pp. 973-990. |
| Noakes et al., “Exploiting retrograde transport of Shiga-like toxin 1 for the delivery of exogenous antigens into the MHC class I presentation pathway”, FEBS Letters, vol. 453, 1999, pp. 95-99. |
| Ohmura-Hoshino et al., “Non-toxic Stx derivatives from Escherichia coli possess adjuvant activity for mucosal immunity”, Vaccine, vol. 22, 2004 (Available online Apr. 22, 2004), pp. 3751-3761. |
| O'Loughlin et al., “Effect of Shiga toxin and Shiga-like toxins on eukaryotic cells”, Microbes and Infection, vol. 3, 2001, pp. 493-507. |
| Partial European Search Report, dated Feb. 4, 2002, for European Application No. 01400255.4. |
| Perera et al., “Identification of Three Amino Acid Residues in the B Subunit of Shiga Toxin and Shiga-Like Toxin Type II That Are Essential for Holotoxin Activity”, Journal of Bacteriology, vol. 173, No. 3, Feb. 1991, pp. 1151-1160. |
| Pruimboom-Brees et al., “Cattle lack vascular receptors for Escherichia coli 0157:H7 Shiga toxins”, PNAS, vol. 97, No. 19, Sep. 12, 2000, pp. 10325-10329. |
| Rapak et al., “Retrograde transport of mutant ricin to the endoplasmic reticulum with subsequent translocation to cytosol”, Proc. Natl. Acad. Sci. USA, Cell Biology, vol. 94, Apr. 1997, pp. 3783-3788. |
| Ryd et al., “Induction of a humoral immune response to a Shiga toxin B subunit epitope expressed as a chimeric LamB protein in a Shigella flexneri live vaccine strain”, Microbial Pathogenesis, vol. 12, 1992, pp. 399-407. |
| Sandvig et al., “Retrograde Transport from the Golgi Complex to the ER of Both Shiga Toxin and the Nontoxic Shiga B-fragment Is Regulated by Butyric Acid and cAMP”, The Journal of Cell Biology, vol. 126, No. 1, Jul. 1994, pp. 53-64. |
| Sandvig et al., “Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum”, Nature, vol. 358, Aug. 6, 1992, pp. 510-512. |
| Sandvig et al., “Transport of protein toxins into cells: pathways used by ricin, cholera toxin and Shiga toxin”, FEBS Letters, vol. 529, 2002 (First published online Aug. 14, 2002), pp. 49-53. |
| Sandvig, “Shiga toxins”, Toxicon, vol. 39, 2001, pp. 1629-1635. |
| Schelte et al., “Differential Reactivity of Maleimide and Bromoacetyl Functions with Thiols: Application to the Preparation of Liposomal Diepitope Constructs”, Bioconjugate Chem, vol. 11, 2000, pp. 118-123. |
| Schoen et al., “Bacteria as DNA vaccine carriers for genetic immunization”, International Journal of Medical Microbiology, vol. 294, 2004, pp. 319-335. |
| Seidah et al., “Complete Amino Acid Sequence of Shigella Toxin B-chain”, The Journal of Biological Chemistry, vol. 261, No. 30, Oct. 25, 1986, pp. 13928-13931. |
| Shigematsu et al., “Site-directed lipid modification of IgG-binding protein by intracellular bacterial lipoprotein process”, Journal of Biotechnology, vol. 75, 1999, pp. 23-31. |
| Stenmark et al., “Peptides Fused to the Amino-Terminal End of Diphtheria Toxin Are Translocated to the Cytosol”, The Journal of Cell Biology, vol. 113, No. 5, Jun. 1991, pp. 1025-1032. |
| Su et al., “Construction of Stable LamB-Shiga Toxin B Subunit Hybrids: Analysis of Expression in Salmonella typhimurium aroA Strains and Stimulation of B Subunit-Specific Mucosal and Serum Antibody Responses”, Infection and Immunity, vol. 60, No. 8, Aug. 1992, pp. 3345-3359. |
| Su et al., “Extracellular export of Shiga toxin B-subunit/haemolysin A (C-terminus) fusion protein expressed in Salmonella typhimurium aroA-mutant and stimulation of B-subunit specific antibody . . . ,” Microbial Pathogenesis, vol. 13, No. 6, Dec. 1992, pp. 465-476, abstract only provided. |
| Tarragó-Trani et al., “A method for the purification of Shiga-like toxin 1 subunit B using a commercially available galabiose-agarose resin”, Protein Expression and Purification, vol. 38, 2004 (Available online Oct. 5, 2004), pp. 170-176. |
| Tarragó-Trani et al., “Shiga-like Toxin Subunit B (SLTB)-Enhanced Delivery of Chlorin e6 (Ce6) Improves Cell Killing”, Photochemistry and Photobiology, vol. 82, 2006 (Published online Nov. 7, 2005), pp. 527-537. |
| Tzschaschel et al., “Towards a vaccine candidate against Shigella dysenteriae 1: expression of the Shiga toxin B-subunit in an attenuated Shigella flexneri aroD carrier strain”, Microbial Pathogenesis, vol. 21, 1996, pp. 277-288. |
| U.S. Advisory Action, dated Jan. 19, 2012, for U.S. Appl. No. 12/569,007. |
| U.S. Advisory Action, dated Oct. 13, 2006, for U.S. Appl. No. 10/628,415. |
| U.S. Notice of Allowance, dated Jun. 29, 2009, for U.S. Appl. No. 10/628,415. |
| U.S. Notice of Allowance, dated Jun. 6, 2014, for U.S. Appl. No. 12/569,007. |
| U.S. Office Action, dated Apr. 12, 2006, for U.S. Appl. No. 10/628,415. |
| U.S. Office Action, dated Apr. 25, 2007, for U.S. Appl. No. 10/628,415. |
| U.S. Office Action, dated Aug. 2, 2005, for U.S. Appl. No. 10/628,415. |
| U.S. Office Action, dated Feb. 4, 2011, for U.S. Appl. No. 12/569,007. |
| U.S. Office Action, dated Jan. 27, 2005, for U.S. Appl. No. 10/628,415. |
| U.S. Office Action, dated Nov. 1, 2013, for U.S. Appl. No. 12/569,007. |
| U.S. Office Action, dated Oct. 31, 2008, for U.S. Appl. No. 10/628,415. |
| U.S. Office Action, dated Oct. 7, 2011, for U.S. Appl. No. 12/569,007. |
| Vingert et al., “The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity”, Eur. J. Immunol, vol. 36, 2006, pp. 1124-1135. |
| Waldrep, “New Aerosol Drug Delivery Systems for the Treatment of Immune-Mediated Pulmonary Diseases”, Drugs of Today, vol. 34, No. 6, 1998, pp. 549-561. |
| Xu et al., “Immunogenicity of an HIV-1 gag DNA vaccine carried by attenuated Shigella”, Vaccine, vol. 21, 2003, pp. 644-648. |
| Number | Date | Country | |
|---|---|---|---|
| 20150045536 A1 | Feb 2015 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 12569007 | Sep 2009 | US |
| Child | 14478687 | US | |
| Parent | 10628415 | Jul 2003 | US |
| Child | 12569007 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/EP02/01627 | Feb 2002 | US |
| Child | 10628415 | US |
